North America Alpha-Glucosidase Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The North American alpha-glucosidase inhibitors market is segmented by geography (United States, Canada, and the rest of North America). The report offers the value (in USD million) and volume (in units) for the above segments.

North America Alpha-Glucosidase Inhibitors Market Size

View Global Report

Compare market size and growth of North America Alpha-Glucosidase Inhibitors Market with other markets in Healthcare Industry

North America Alpha-Glucosidase Inhibitors Market Analysis

The North America Alpha-Glucosidase Inhibitors Market size is estimated at USD 0.29 billion in 2025, and is expected to reach USD 0.32 billion by 2030, at a CAGR of 2.5% during the forecast period (2025-2030).

In North America, the United States has the highest number of COVID cases with 82 million by April 2022, the country also registered the highest death rate. According to the Diabetes Voice article published in May 2020, close to 40,000 deaths are people with diabetes. In the North American region diabetes patients are more concerned about stocking up the monitoring and managing devices due to this the market increased during these years.

The North American region has witnessed an astounding increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. According to FDA, comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people. Patients with Type 2 diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates.

The World Health Assembly agreed on a Resolution to strengthen diabetes prevention and control in May 2021. It recommends actions such as increasing access to diabetes medicines and health products and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to market transparency for diabetes medicines and health products.

The FDA approves AGIs for the treatment of type 2 diabetes mellitus. They have shown some benefits in type 1 diabetes mellitus and gestational diabetes mellitus but are not FDA-approved for these indications. Acarbose has been shown to decrease body weight in a worldwide observational study. AGIs are particularly useful for reducing postprandial hyperglycemia. They modestly decrease glycosylated hemoglobin levels and also reduce postprandial insulin concentration. Compared with oral antihyperglycemic drugs, they also reduce glucose variability throughout the day. They, however, do not affect fasting insulin and serum triglyceride concentrations.

This is driving the demand for Alpha-Glucosidase Inhibitors in North America, thereby driving the market in focus during the forecast period.

North America Alpha-Glucosidase Inhibitors Industry Overview

The North American alpha-glucosidase inhibitors market studied is highly fragmented into many manufacturers like Bayer, SunPharma, Pfizer, and Takeda, holding a presence in all regions.

North America Alpha-Glucosidase Inhibitors Market Leaders

  1. Takeda

  2. Pfizer

  3. Bayer

  4. Sunpharma

  5. Glenmark

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF

North America Alpha-Glucosidase Inhibitors Market News

  • April 2023: A study was planned to move towards drug repurposing by utilizing Food and Drug Administration (FDA)-approved drugs against glucosidase and investigating the molecular mechanisms. The target protein was refined and optimized by introducing missing residues and minimizing clashes to find the potential inhibitor against glucosidase.
  • July 2022: The drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), fixed the prices of 84 drug formulations, including those used for the treatment of diabetes. According to the order, a single tablet of Voglibose was expected to cost Rs 10.47 (USD 0.13), excluding GST.

North America Alpha-Glucosidase Inhibitors Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET INDICATORS

  • 5.1 Type-1 Diabetes Population
  • 5.2 Type-2 Diabetes Population

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Pfizer
    • 6.1.2 Glenmark pharma
    • 6.1.3 Sun pharma
    • 6.1.4 Torrent
    • 6.1.5 Unichem
    • 6.1.6 Hexalag
  • *List Not Exhaustive
  • 6.2 Company Share Analysis

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
* We will provide a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents. **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments.
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

North America Alpha-Glucosidase Inhibitors Industry Segmentation

Type-2 diabetes is treated with medications called alpha-glucosidase inhibitors. This family of pharmaceuticals consists of two drugs: acarbose (Precose) and miglitol (Glyset). The North America alpha-glucosidase inhibitors market is segmented by geography (United States, Canada, and the Rest of North America). The report offers the value (in USD) and volume (in units) for the above segments. This report will provide a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.

Need A Different Region or Segment?
Customize Now

North America Alpha-Glucosidase Inhibitors Market Research FAQs

How big is the North America Alpha-Glucosidase Inhibitors Market?

The North America Alpha-Glucosidase Inhibitors Market size is expected to reach USD 0.29 billion in 2025 and grow at a CAGR of 2.5% to reach USD 0.32 billion by 2030.

What is the current North America Alpha-Glucosidase Inhibitors Market size?

In 2025, the North America Alpha-Glucosidase Inhibitors Market size is expected to reach USD 0.29 billion.

Who are the key players in North America Alpha-Glucosidase Inhibitors Market?

Takeda, Pfizer, Bayer, Sunpharma and Glenmark are the major companies operating in the North America Alpha-Glucosidase Inhibitors Market.

What years does this North America Alpha-Glucosidase Inhibitors Market cover, and what was the market size in 2024?

In 2024, the North America Alpha-Glucosidase Inhibitors Market size was estimated at USD 0.28 billion. The report covers the North America Alpha-Glucosidase Inhibitors Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the North America Alpha-Glucosidase Inhibitors Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Page last updated on: February 10, 2025

North America Alpha-Glucosidase Inhibitors Industry Report

Statistics for the 2025 North America Alpha-Glucosidase Inhibitors market share, size and revenue growth rate, created by Mordor Intelligenceâ„¢ Industry Reports. North America Alpha-Glucosidase Inhibitors analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

North America Alpha-Glucosidase Inhibitors Market Report Snapshots